The Evolution of Oligometastatic Pancreatic Ductal Adenocarcinoma: From Anatomic Description to Biologically Informed Patient Selection

Metastatic pancreatic ductal adenocarcinoma (PDAC) has historically been managed with systemic therapy, and local therapies have, in general, been avoided in the absence of symptoms directly related to a specific metastasis. Even if a specific site of disease, such as a local recurrence, had the potential to cause symptoms in the future, there was a bias against prophylactic palliation. It was well-established that most patients die of systemic progression. This approach is now under pressure from four directions. Retrospective case series have reported survival durations longer than anticipated in highly selected patients with low-volume, single-organ disease. A randomized phase II trial reported that metastasis-directed therapy prolonged progression-free survival. Biologic data indicate that the site of metastatic relapse is encoded in gene expression profiles already present in the primary tumor. Second-line systemic therapy has become substantially more effective, which lengthens the interval over which control of an untreated metastasis may become clinically important. We trace the oligometastatic concept from the 1995 Hellman and Weichselbaum hypothesis to the 2026 OligoPanc consensus definition of up to three lesions confined to a single organ, examine the criteria proposed for patient selection, summarize the surgical and ablative radiotherapy literature, and consider the trials that will determine whether this is a treatable disease state or a favorable prognostic phenotype. We conclude that induction systemic therapy, followed by response assessment that weighs the absence of disease progression, Carbohydrate Antigen 19-9 (CA19-9) kinetics, and performance status, is a defensible route to local therapy directed at the metastases and the primary tumor, and warrants prospective study.